Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2021 Apr;17(12):1449-1458.
doi: 10.2217/fon-2020-1048. Epub 2021 Jan 11.

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek  1 , Chih-Cheng Chen  2 , Miklós Egyed  3 , Martin Ellis  4 , Laura Fox  5 , Yeow T Goh  6 , Vikas Gupta  7 , Claire Harrison  8 , Jean-Jacques Kiladjian  9 , Mihaela C Lazaroiu  10 , Adam Mead  11 , Donal McLornan  12 , Mary F McMullin  13 , Stephen T Oh  14 , Andrew Perkins  15 , Uwe Platzbecker  16 , Christof Scheid  17 , Alessandro Vannucchi  18 , Sung-Soo Yoon  19 , Mark M Kowalski  20 , Ruben A Mesa  21
Affiliations
Free article
Comparative Study

MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic

Srdan Verstovsek et al. Future Oncol. 2021 Apr.
Free article

Abstract

Hallmark features of myelofibrosis (MF) are cytopenias, constitutional symptoms and splenomegaly. Anemia and transfusion dependency are among the most important negative prognostic factors and are exacerbated by many JAK inhibitors (JAKi). Momelotinib (MMB) has been investigated in over 820 patients with MF and possesses a pharmacological and clinical profile differentiated from other JAKi by inhibition of JAK1, JAK2 and ACVR1. MMB is designed to address the complex drivers of iron-restricted anemia and chronic inflammation in MF and should improve constitutional symptoms and splenomegaly while maintaining or improving hemoglobin in JAKi-naive and previously JAKi-treated patients. The MOMENTUM Phase III study is designed to confirm and extend observations of safety and clinical activity of MMB.

Keywords: ACVR1; JAK inhibitor; Phase III clinical trial; anemia; danazol; hemoglobin; momelotinib; myelofibrosis; transfusion.

Plain language summary

Lay abstract The most important features of myelofibrosis (MF) are low blood cell counts and symptoms including tiredness, night sweats and itching, along with increased size of the spleen, which may cause a feeling of fullness and pain. Low red blood cell counts (anemia) may mean regular blood transfusions are needed and this is one of the signs MF is getting worse. Drugs called JAK inhibitors (JAKi) are available to treat MF, but can have a side effect of making blood cell counts lower. Momelotinib (MMB) is a different type of JAKi to the ones currently available, and is an experimental drug for MF. MMB is designed to treat symptoms and spleen like other JAKi, but also to improve blood cell counts. MMB has already been given to more than 820 patients with MF in other clinical studies. Some of the patients in these studies had been treated with different JAKi before, and others got MMB as their first JAKi treatment. The MOMENTUM Phase III study is designed to collect more information on the safety and effectiveness of MMB in MF.

PubMed Disclaimer

Publication types

MeSH terms

LinkOut - more resources